The Fragile Chain: How One Logistics Provider's 701-Trial Backlog Exposes a Global Cell Therapy Bottleneck
Cryoport, the world's dominant provider of cryogenic logistics for cell and gene therapies, is supporting 701 active clinical trials across the globe while simultaneously managing commercial supply chains for 19 approved therapies. As the international cell therapy pipeline accelerates — driven by regulators in the US, EU, Japan, and beyond — the gap between demand and specialized cold-chain capacity is emerging as one of the sector's most consequential systemic risks. A single high-profile fail
ViaNews Editorial Team•